Trifloromethylbenzimidazole Suppresses Cervical Cancer Growth via Targeting Mammalian Large Tumor Suppressor Kinase

The present study investigated the action of triflorobenzimidazole (TFBI) against cervical cancer cells and evaluated the associated mechanism. The proliferative potential of HeLa cells was suppressed to 27% and those of Caski cells to 19% at 48 h of treatment with 10 mu M TFBI. The cellular fraction showed significant increase in G1/G0 phase in TEM-treated HeLa and Caski cells. The apoptotic cellular proportion was enhanced to 68.54 and 74.82% in HeLa and Caski cells, respectively, on treatment with 10 mu M TEB1. The level of M MP-9 and cyclin E in both the tested cell lines was down-regulated by TFBI treatment. The YAP phosphorylation and LATS1 expression was promoted by TFBI in the cells. In summary, TFBI exhibits inhibitory effect on cervical cancer cells via increase of G1/G0 cellular content and activation of apoptosis. Moreover, TFBI elevated YAP phosphorylation and expression of LATS1. Therefore, TFBI may be used to develop chemotherapy for cervical cancer.